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Hemodialysis-Induced Release
of Hemoglobin Limits Nitric Oxide
Bioavailability and Impairs Vascular Function
Christian Meyer, MD,* Christian Heiss, MD,* Christine Drexhage, MSC,* Eva S. Kehmeier, MD,*
Jan Balzer, MD,* Anja Mühlfeld, MD,† Marc W. Merx, MD,* Thomas Lauer, MD,*
Harald Kühl, MD,‡ Jürgen Floege, MD,† Malte Kelm, MD,* Tienush Rassaf, MD*
Duesseldorf and Aachen, Germany
Objectives This study sought to characterize the impact of hemodialysis (HD)-induced release of hemoglobin on the bio-
availability of nitric oxide (NO) and endothelial function.
Background Patients on chronic HD suffer from endothelial dysfunction and a massively increased risk for cardiovascular
events. Although dialysis-dependent and -independent factors are discussed, the exact mechanisms are not fully
understood.
Methods In 14 HD patients (56  15 years of age), endothelial function was determined by measuring flow-mediated di-
lation (FMD) of the brachial artery using high-resolution ultrasound before and after treatment. The NO consump-
tion activity of plasma isolated from patients before and after hemodialysis was studied with an NO-sensitive
electrode.
Results HD impaired FMD (3.5  2.6% to 1.7  1.4%, p  0.04) without affecting brachial artery diameter (4.7  0.6
mm vs. 4.4  0.9 mm, p  0.27). This was accompanied by an increase in cell-free plasma hemoglobin (196 
43 mg/l to 285  109 mg/l, p  0.01), which led to a decrease in the bioavailability of free NO by more than
70%. Oxidation of the released plasma ferrous hemoglobin prevented the consumption of NO. The amount of
decompartmentalized hemoglobin after HD correlated inversely with the change in FMD (r  0.65, p  0.041).
Conclusions Our data support a role of HD-induced release of hemoglobin in the pathogenesis of endothelial dysfunction
in patients with end-stage renal disease. Approaches that oxidize free plasma hemoglobin may restore NO
bioavailability and may have potential beneficial effects on vascular function. (Influence of Hemodialysis on
Endothel-Depending Dilatation of Peripheral Arteries; NCT00764192) (J Am Coll Cardiol 2010;55:454–9)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.068d
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Nardiovascular complications are the major cause of death
n patients with end-stage renal disease (ESRD) undergoing
emodialysis (HD) (1). Endothelial dysfunction is an early
ey step in the development of atherosclerosis (2) and has
een attributed to impaired nitric oxide (NO) bioactivity as
ell as enhanced formation of oxygen-derived free radicals
3). Previous reports showed a decline in NO bioactivity
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Manuscript received April 9, 2009; revised manuscript received July 7, 2009,
ccepted July 12, 2009.uring HD (4). The underlying mechanisms of altered NO
ioavailability in these patients are not fully understood.
lthough activation of cytokines during HD may increase
he production of NO (5), NO might be decreased because
f increased degradation, diminished NO synthase activity
6), altered serum levels of asymmetric dimethylarginine (7),
ecreased bioavailability of L-arginine (8), and/or a removal
f NO metabolites by dialysis itself (4).
See page 460
Gladwin et al. (9) have recently reported a novel mech-
nism by which the bioavailability of NO is dramatically
educed during decompartmentalization of hemoglobin.
entral to this investigation is the understanding that free
O is scavenged at least 1,000 times more rapidly byell-free hemoglobin than by red blood cells. The rates of
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February 2, 2010:454–9 Vascular Function During HemodialysisO consumption by cell-free and intraerythrocytic hemo-
lobin suggest that only when hemoglobin is physically
ompartmentalized within red blood cells will endothelium-
erived NO reach concentrations within smooth muscle
ecessary to activate guanylyl cyclase and cause vasodilation
10). This mechanism has been associated with the vascu-
opathy of hereditary, acquired, and iatrogenic hemolytic
tates (11). Importantly, intravascular hemolysis has also
een described during HD (12,13). Whether decompart-
entalization of hemoglobin contributes to impaired endo-
helial function in patients undergoing HD is unknown. We
herefore hypothesized that HD increases cell-free plasma
emoglobin, which then blunts endothelial function by
cavenging NO.
ethods
tudy design. In this proof-of-concept study, vascular
unction and blood parameters were studied immediately
efore and within 30 min after a single HD session in
atients with ESRD. The NO scavenging activity of plasma
rom patients before and after HD was determined by an
O-sensitive electrode. The study protocol was approved
y the institutional review board, and all patients gave
ritten informed consent.
atients. Patients with ESRD (21 to 80 years of age) who
ad been on chronic HD for at least 6 months were investi-
ated. Other cardiovascular risk factors and pre-existing car-
iovascular disease did not preclude patients from participation
n the study. Exclusion criteria were congestive heart failure
ith a cardiac ejection fraction of 30%, HD-associated
ypotension, severe cardiac arrhythmias, acute inflammation
C-reactive protein 5 mg/l), and heart rhythm other than
inus.
D. All patients underwent HD 3 times per week with a
ession time of 4 h. All patients were dialyzed with a synthetic
ow-flux hollow-fiber filter (polysulfone, F-series, Fresenius
edical Care, Bad Homburg, Germany) with a mean blood
ump speed of 296  97 ml/min. Bicarbonate-buffered dialy-
ate was used in all sessions. The ultrafiltration rate during the
D procedure was set to reach individual dry weight.
ltrasound measurement of flow-mediated vasodilation.
ndothelial function was measured as flow-mediated dilation
FMD) of the brachial artery as recently described (14). Briefly,
he diameter of the brachial artery was measured 1 to 2 cm
bove the cubital fossa before and after ischemia of the forearm
sing a 15-MHz transducer (Vivid 7, GE Healthcare, Prince-
on, New Jersey) (15). Endothelium-independent dilation was
easured 4 min after sublingual application of 400-g glycerol
rinitrate (GTN) after HD because GTN may influence
emodynamics and NO bioavailability (16).
easurements of blood pressure, standard clinical blood
arameters, arginase 1, and cell-free plasma hemoglobin.
lood pressure was measured by a sphygmomanometric cuff.
lood was drawn through large-bore angiocatheters to pre-
ent artifactual hemolysis into pre-chilled tubes. Standard
linical blood parameters, including parameters of hemolysis wnd anemia, were immediately an-
lyzed in a central laboratory using
tandard techniques. Cell-free he-
oglobin was measured in plasma
ia the QuantiChrom Hemoglo-
in Assay Kit (BioAssaySystems,
ayward, California). Plasma lev-
ls of arginase 1, a cytosolic protein
ound predominantly in liver and
ed blood cells (17), were mea-
ured via enzyme-linked immuno-
orbent assay (Human Arginase 1
LISA Test-kit, Hycult Biotechnology, Uden, the Nether-
ands; n  5).
O consumption assay. The NO consumption was mea-
ured using an NO-sensitive electrode as described (9,18). The
O scavenging activity of test substances was measured as a
ecrease in electrode current, indicating lower NO concentra-
ion in the solution. The NO was generated in situ by the
ecay of the NO donor PROLI NONOate (Cayman Chem-
cal, Axxora, Loerrach, Germany), in argon-purged, essentially
naerobic, phosphate-buffered saline at pH 7.4 (9,19). The
O was continuously monitored with an ISO-NO Mark-II
O meter and an amperometric, NO-specific electrode (WPI
urope, Berlin, Germany) (9,20). Plasma samples (50 l) were
dded into the reaction chamber by means of a gas-tight
yringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) after
O production by the NO donor reached a stable plateau. The
O consumption was quantitated by dividing the instanta-
eous decrease in electrode current produced on the addition of
amples by the slope of the standard curve, which was gener-
ted by additions of oxyhemoglobin standards. Ferricyanide
FeCN) oxidizes Fe2 in the heme group to Fe3, thereby
bolishing the NO-binding capacity of hemoglobin (9). To
how that the NO-scavenging activity of plasma is heme
ependent, potassium FeCN was added to post-HD patient
lasma (2 mmol/l) and incubated for 15 min.
tatistical analysis. Continuous variables are presented as
ean  SD. Pre- and post-HD values were compared using
aired t tests. Univariate correlations were Pearson correlations.
multivariate regression analysis was performed to determine
ndependent predictors of the change in FMD. Values of p 
.05 were considered to be statistically significant. Statistical
nalyses were performed using SPSS version 14.0 (SPSS Inc.,
hicago, Illinois).
esults
atient characteristics. The clinical baseline characteris-
ics are shown in Table 1. The ESRD resulted from diabetic
ephropathy (n  2), nephrosclerosis (n  2), polycystic
idney disease (n  3), suspected glomerulonephritis (n 
), and hypertensive/vascular renal damage (n  4). The
verage dialysis vintage was 30  23 months. Ultrafiltration
1,385  598 ml) varied according to the patient’s actual
Abbreviations
and Acronyms
ESRD  end-stage renal
disease
FeCN  ferricyanide
FMD  flow-mediated
dilation
GTN  glycerol trinitrate
HD  hemodialysis
NO  nitric oxideeight. The latter decreased during HD from 76 14 kg to
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Vascular Function During Hemodialysis February 2, 2010:454–94 14 kg after HD (p 0.001). None of the patients had
eceived blood transfusions during the preceding 6 months.
D leads to decompartmentalization of hemoglobin. The
otal concentration of hemoglobin was unaffected by HD
114  15 g/l vs. 115  15 g/l, p  0.8). Cell-free
emoglobin (196 43 mg/l; equivalent to 19.6 4.3 mg/dl
12.2  9.1 M] heme) was elevated in patients at baseline
efore HD as compared with values reported for control
ubjects who are in the nanomolar range (9). Hemodialysis
ed to a significant further increase in cell-free plasma
emoglobin to 285  109 mg/l (equivalent to 28.5  10.9
g/dl [16.8  4.8 M] heme) (p  0.01) (Fig. 1),
ndicating decompartmentalization of hemoglobin. This
as accompanied by an increase in plasma arginase 1
oncentrations (1.8  0.4 ng/ml to 2.7  0.2 ng/ml, p 
.03), which is characteristic for red blood cell damage. No
igns of apparent hemolysis were observed as evidenced by
nchanged levels of lactate dehydrogenase, bilirubin, hap-
oglobin, and red blood cells (Table 2).
D leads to a decrease in FMD. Endothelial vasodilator
unction as measured by FMD decreased after HD as
linical Characteristics of Hemodialysis PatientsTable 1 Clinical Characteristics of Hemodialysis Patients
n (male/female) 14 (12/2)
Age, yrs 56 15
BMI, kg/m2 24 4
Current smoker 3
Past smoker 2
Diabetes mellitus 3
Hypertension 9
Dyslipidemia 6
CAD 6
1-vessel 1
2-vessel 1
3-vessel 4
CVD 3
Time on dialysis, months 30 23
Medication
Beta-blockers 12
ACE inhibitors/AT-II antagonists 7
Calcium antagonists 5
Central sympatholytics 4
Diuretic agents 8
Statins 4
Oral antidiabetes agents 1
Insulin 2
Blood parameters
Serum protein, g/l 67 9
Serum albumin, g/l 40 7
Total cholesterol, mg/dl 154 43
HDL cholesterol, mg/dl 51 13
LDL cholesterol, mg/dl 95 37
Triglycerides, mg/dl 156 55
Plasma glucose, mg/dl 97 24
alues are n or mean  SD.
ACE  angiotensin-converting enzyme; AT-II  angiotensin II type 1 receptor; BMI  body mass
ndex; CAD  coronary artery disease; CVD  cerebrovascular disease; HDL  high-density
ipoprotein; LDL  low-density lipoprotein.ompared with baseline (3.5  2.6% vs. 1.7  1.4%, p .04) (Fig. 1). The GTN response as measured after HD
as 7.6  3.7%, showing that the smooth muscle compart-
ent was still responsive to NO.
No differences were seen in baseline diameters of the
rachial artery (4.7  0.6 mm vs. 4.4  0.9 mm, before vs.
fter HD, p  0.27) or in blood flow at baseline (106  32
l/min vs. 111  32 ml/min, p  0.81) and during
yperemia (652  209 ml/min vs. 655  138 ml/min, p 
.94). This confirmed that the degree of shear stress
epresenting the driving force of FMD was unaffected
Table 2).
ell-free hemoglobin inversely correlates with the
hange in FMD. The change in FMD univariately corre-
ated inversely with the baseline diameter of the brachial
rtery (r  0.65, p  0.029), with erythrocytes (r  0.56,
 0.046), as well as inversely with cell-free plasma
emoglobin (r  0.65, p  0.041) (Table 3) after HD.
O consumption by cell-free hemoglobin. To provide a
echanistic link between decreased NO-dependent va-
odilation and HD-associated decompartmentalization of
emoglobin, the NO consumption of plasma isolated
rom patients before and after HD was tested ex vivo and
ompared with oxyhemoglobin standards (Fig. 2).
ost-HD plasma containing 28.3  5.7 M heme
onsumed significantly more NO (14.0  4.1 M vs. 8.0
5.3 M, p  0.02) as compared with pre-HD plasma
ontaining 12.4  4.3 M heme (Fig. 3). Consistent
ith rapid dioxygenation or nitrosylation by plasma
emoglobin, or other ferrous heme species, the quantity
f NO consumed by plasma correlated with plasma
emoglobin-related heme levels (r  0.7, p  0.01). The
lope of the linear least-square fit (0.66 M NO/M
Figure 1 Decompartmentalization of Hb Is
Associated With Endothelial Dysfunction During HD
Cell-free plasma hemoglobin (cell-free Hb) increases from 196  43 mg/l
(equivalent to 19.6  4.3 mg/dl [12.2  9.1 M] heme) to 285  109 mg/l
(equivalent to 28.5  10.9 mg/dl [16.8  4.8 M] heme), and flow-mediated
dilation (FMD) significantly decreases during a single hemodialysis (HD) ses-
sion. Data given as mean  SD (n  14). *Each p  0.05.
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February 2, 2010:454–9 Vascular Function During Hemodialysiseme) indicates that nearly 70% of the measurable
emoglobin-related heme is competent to consume NO.
hemoglobin-based mechanism for NO consumption
as further substantiated by the elimination of plasma
O-consuming activity by potassium FeCN, which oxi-
izes ferrous hemoglobin to methemoglobin. The FeCN
educed the post-HD plasma consumption of NO to
evels observed with pre-HD plasma (Fig. 3). These data
ndicate that an HD-related increase in NO-consuming
ctivity of patient plasma is iron dependent and is related
o the heme concentrations of this plasma, which nearly
toichiometrically consumes micromolar quantities of NO.
iscussion
he key findings of the present study are: 1) HD leads to a
ecompartmentalization of hemoglobin with an increase in
ell-free plasma hemoglobin after a single HD session;
) FMD is impaired during HD, and the degree of im-
airment is determined by cell-free hemoglobin levels; and
) the NO scavenging activity of post-HD plasma is linked
o the decompartmentalized hemoglobin and can be re-
ersed by oxidation of the ferrous hemoglobin.
Corroborating previous studies, we observed an acutely
lunted endothelial function as measured by FMD after a
ingle HD session (21–23). The FMD of the brachial
Hemodynamics, Vascular Function, and Blood PTable 2 Hemodynamics, Vascular Function,
Befor
Hemodynamics
MAP, mm Hg 103
Heart rate, beats/min 70
Vascular function
Diameter BA, mm 4.7
FMD, % 3.5
GTN, % N
Blood parameters
Serum creatinine, mg/dl 8.5
Blood urea nitrogen, mg/dl 116
Potassium, mM/l 4.8
Calcium, mM/l 2.2
Phosphate, mM/l 1.7
Erythrocytes, T/l 3.6
Reticulocytes, G/l 76
Hemoglobin, g/l 114
Cell-free Hb, mg/l 196
Cell-free Hb (in heme), mg/dl (M) 19.6 4.3 (
Arginase 1, ng/ml 1.8
Hematocrit, % 34
Haptoglobin, g/l 1.6
Total bilirubin, mg/dl 0.7
Lactate dehydrogenase, mg/dl 215
Iron, M/l 14
Ferritin, g/l 566
Transferrin, g/l 1.9
Transferrin saturation, % 30
BA brachial artery; FMD flow-mediated dilation; GTN glycerol trin
ND  not defined.arameters Before and After HDand Blood Parameters Before and After HD
e HD After HD p Value
18 99 22 0.6
11 71 11 0.9
0.6 4.4 0.9 0.3
2.6 1.7 1.4 0.04
D 7.6 3.7
3.3 3.9 1.8 0.01
31.0 42 13.5 0.01
0.7 3.9 0.4 0.01
0.4 2.2 0.4 0.5
0.7 0.9 0.4 0.01
0.4 3.5 0.4 0.7
34 79 34 0.9
15 115 15 0.8
43 285 109 0.01
12.2 9.1) 28.5 10.9 (16.8 4.8) 0.01
0.4 2.7 0.2 0.03
4 36 4 0.08
1.1 1.4 0.7 0.6
0.4 0.8 0.4 0.4
52 217 52 0.4
7 15 7 0.7
325 566 325 0.9
0.4 1.9 0.4 0.7
19 37 19 0.2rtery is almost entirely NO synthase–dependent, corre- Anivariate Analysis for Predictors of thehange in FMD During a Single HD SessionTable 3 Univariate Analysis for Predictors of theChange in FMD During a Single HD Session
 FMD
r p Value
Risk factors
BMI 0.35 0.238
MAP 0.11 0.704
Total cholesterol 0.44 0.132
Age 0.21 0.485
Glucose 0.18 0.59
Vascular function
Diameter BA 0.65 0.029
GTN-induced dilation 0.22 0.561
Hemodialysis parameters
Serum creatinine 0.43 0.181
Blood urea nitrogen 0.08 0.808
Ultrafiltration 0.12 0.745
Blood pump speed 0.14 0.659
Hemolysis parameters
Erythrocytes 0.56 0.046
Reticulocytes 0.09 0.846
Cell-free hemoglobin 0.65 0.041
Arginase 1 0.75 0.245
Haptoglobin 0.07 0.861
Lactate dehydrogenase 0.33 0.518
Total bilirubin 0.43 0.158bbreviations as in Tables 1 and 2.
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Vascular Function During Hemodialysis February 2, 2010:454–9ates with endothelial function of most conduit arteries,
nd can therefore be used as a surrogate for systemic NO
ioactivity (24). Here we show the concept that HD leads
o the release of hemoglobin, which limits free NO
ioavailability. The NO reacts with oxyhemoglobin in a
apid and irreversible reaction that produces nitrate and
ethemoglobin. The speed and irreversibility of this reac-
ion is such that small amounts of cell-free hemoglobin are
ufficient to completely offset endothelial NO production
nd result in endothelial dysfunction (20). This study is the
rst to test this theory in an iatrogenic setting. Alternative
xplanations of the impaired NO-dependent vasodilation
nclude arginase-dependent depletion of the NO synthase
ubstrate L-arginine in vivo. However, our in vitro data
how that the majority of NO scavenging activity of
ost-HD patient plasma is explained by the plasma cell-free
emoglobin/heme content. Furthermore, a predominant
emoglobin-based mechanism responsible for NO con-
umption in the HD patients presently studied is supported
y the elimination of plasma NO consumption after treat-
ent of plasma with FeCN, leading to transition of Fe(II)
emoglobin to methemoglobin. Future studies are necessary
o define the time dependence of these effects and to show
hether clearance or therapeutic removal of cell-free hemo-
lobin leads to restoration of NO bioavailability and hence
ndothelial function.
Figure 2 HD Increases NO Consumption in Plasma
Original nitric oxide (NO)-sensitive electrode registration showing that
plasma from a patient post-hemodialysis (HD) (dotted green line) con-
sumes more NO than plasma from the same patient pre-HD (dotted blue
line). The NO was generated in situ, which we measured using amperomet-
rics (current in pA). The NO donor and plasma samples additions are indi-
cated by arrows. (Inset) Representative plot of the change in current (pA)
in response to cell-free oxyhemoglobin (OxyHb) standards in phosphate-buff-
ered solution at pH 7.4. The solid red line represents the linear best fit to
the data. Data given as mean  SD (n  3). Ronclusions
ur data suggest that HD-induced release of hemoglobin
lays an important role in the pathogenesis of endothelial
ysfunction in patients with ESRD. This mechanism is
ikely to be relevant for other medical interventions that
ntail red blood cell damage, including coronary artery
ypass grafting, cell-saver interventions, extracorporeal
embrane oxygenation, and transfusion of aged blood.
herapies that inactivate cell-free plasma hemoglobin by
xidation, such as inhaled NO gas, NO donor infusions,
nd L-arginine supplementation, restore NO bioavail-
bility and may have potential beneficial effects on
ascular function.
cknowledgments
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eprint requests and correspondence: Dr. Tienush Rassaf,
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Figure 3 Cell-Free Hb Accounts for NO Consumption
The NO consumption by post-HD plasma (green bar) was significantly
greater than that exerted by pre-HD plasma (p  0.05) (blue bar) and was
similar to the effects exerted by 5 and 10 M cell-free Hb standards (17 
5 pA and 30  2 pA, p  0.05, n  3). Confirming Hb dependence of
these effects, the treatment of samples with ferricyanide (FeCN) reduced
NO consumption to control levels (phosphate-buffered saline). Data given
as mean  SD. *p  0.05. Abbreviations as in Figures 1 and 2.assaf@med.uni-duesseldorf.de.
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